AstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO’s expansion push

Unlike some other manufacturers, Samsung Biologics has enjoyed a revenue boost from the novel coronavirus pandemic, and it’s accelerating its expansion plans to match. With a $2 billion “super plant” in the offing, Samsung now has a new Big Pharma supply deal in place to keep driving growth.

AstraZeneca tapped Samsung Biologics for a $331 million supply pact to produce bulk drug substance and “drug product to support AstraZeneca’s biologics therapeutics” at the CMO’s Plant 3 facility in Incheon, South Korea, the partners said Tuesday.

The deal can be expanded to $546 million and will help “accelerate Korean bio-health innovation,” according to a release. 

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

An AstraZeneca spokesman said the supply pact would last “several years” and didn’t specify which biologics products would be included. A Samsung spokesperson could not be reached for comment by press time.

Samsung’s newest supply pact comes as the Korean contract manufacturer revs up its aggressive expansion plans, including building a $2 billion biologics “super plant” that would rank among the largest in the world. 

RELATED: Samsung Biologics plots $2B ‘super plant’ as COVID-19 sends sales through the roof

Source link

Common heart defect—repaired or not—may limit exercise ability

Here Are The Detailed And Risky Steps NASA Needs to Take to Land on The Moon by 2024